Congenital Bleeding Disorder Clinical Trial
— pathfinderâ„¢6Official title:
An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A
Verified date | April 2024 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients (PUPs) with haemophilia A.
Status | Completed |
Enrollment | 125 |
Est. completion date | June 7, 2023 |
Est. primary completion date | June 7, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 0 Years to 6 Years |
Eligibility | Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Male, age below 6 years of age at the time of signing informed consent - Diagnosis of severe haemophilia A (FVIII activity level 1%) based on medical records or central laboratory results - No prior use of purified clotting factor products (5 previous exposures to blood components is acceptable) Exclusion Criteria: - Any history of FVIII inhibitor (defined by medical records) - Known or suspected hypersensitivity to trial product or related products - Previous participation in this trial. Participation is defined as first dose administered of trial product - Receipt of any investigational medicinal product within 30 days before screening - Congenital or acquired coagulation disorder other than haemophilia A - Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise the patient's safety or compliance with the protocol - Patient's parent(s')/legally acceptable representative (LAR(s')) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation |
Country | Name | City | State |
---|---|---|---|
Algeria | Beni Messous Hospital Issaad Hassani | Algiers | |
Algeria | University Hospital Saadna Abdenour of Setif | Setif | |
Argentina | Sanatorio Mayo Privado S.A | Cordoba | |
Australia | Royal Children's Hospital | Parkville | Victoria |
Australia | Lady Cilento Children's Hospital | South Brisbane | Queensland |
Austria | Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie | Graz | |
Austria | Universitätsklinik Kinder-Jugendheilkunde | Innsbruck | |
Austria | Klinikum Klagenfurt am Wörthersee (LKH Klagenfurt) | Klagenfurt | |
Austria | Landes-Frauen und Kinderklinik Linz | Linz | |
Austria | LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde | Salzburg | |
Austria | LKH St. Poelten, Kinder-und Jugendheilkunde | St. Poelten | |
Austria | Universitätsklinik für Kinder- und Jugendheilkunde | Wien | |
Bulgaria | UMHAT "Sveti Georgi" Clinica of Pediatric | Plovdiv | |
Canada | Hamltn Hth Sci/McMstr Child Hosp | Hamilton | Ontario |
France | Hôpital Cardiologique Louis Pradel | Bron Cedex | |
France | Centre régional de traitement de l'Hémophilie | Nantes Cedex 1 | |
France | Hopital Necker | Paris | |
Germany | Werlhof-Institut | Hannover | |
Germany | Uniklinikum des Saarlandes | Homburg/Saar | |
Greece | Aghia Sophia Childrens' Hospital | Athens | |
Greece | 'Ippokrateio' General Hospital of Thessaloniki | Thessaloniki | |
Israel | Sheba MC The Israeli National Hemophilia Center | Tel-Hashomer | |
Italy | AOU Meyer | Firenze | |
Italy | Dipartimento di Ematologia Univ. Firenze | Firenze | |
Italy | A.O.U. Città della Salute e della Scienza di Torino-Ospedale | Torino | |
Japan | Nagoya University Hospital_Blood Transfusion | Aichi | |
Japan | Hyogo prefectural kobe children's hospital | Hyogo | |
Japan | Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics | Kyoto | |
Japan | Saitama Children's Med Centre_Hematology-Oncology | Saitama | |
Japan | Shizuoka Children's Hospital, Hematology-Oncology | Shizuoka | |
Japan | National Center for Child Health and Development_Hematology | Tokyo | |
Malaysia | Hospital Pulau Pinang_Georgetown, Penang | Georgetown, Penang | |
Malaysia | Hospital Wanita dan Kanak-Kanak Kuala Lumpur | Kuala Lumpur | |
Malaysia | National Blood Centre | Kuala Lumpur | |
Romania | 1st Paediatric Department, Fundeni Clinical Institute | Bucharest | |
Romania | Emergency County Hospital Constanta | Constanta | |
Romania | ,,Louis Turcanu'' Emergency Hospital for Children | Timisoara | Timis |
Spain | Hospital Teresa Herrera Materno Infantil . E.O.X.I. A Coruña | A Coruña | |
Spain | Hospital Sant Joan de Déu | Esplugues Llobregat | |
Spain | Hospital Universitario La Paz | Madrid | |
Taiwan | NTU Hospital - Children and Women Hospital | Taipei | |
Thailand | Ramathibodi Hospital_Bangkok | Bangkok | |
Thailand | Hematology and Oncology, Dept.of Pediatrics, CMU | Chiang Mai | |
Thailand | Sunpasitthiprasong Hospital | Ubon Ratchathani | |
United States | Torrence Hemby Ped Hem/Onc Ctr | Charlotte | North Carolina |
United States | Rush University Med. Cntr | Chicago | Illinois |
United States | Dayton's Children's Hemostasis and Thrombosis Center | Dayton | Ohio |
United States | University Of Iowa | Iowa City | Iowa |
United States | Children's Hosp-Los Angeles | Los Angeles | California |
United States | North Shore Long Island Jewish Medical Center | New Hyde Park | New York |
United States | Univ Oklahoma Sci Ctr OK City | Oklahoma City | Oklahoma |
United States | Arizona H&T Phoenix Child Hosp | Phoenix | Arizona |
United States | Univ of Utah Primary Children's Hospital | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
United States, Algeria, Argentina, Australia, Austria, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Japan, Malaysia, Romania, Spain, Taiwan, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of inhibitory antibodies against coagulation factor VIII (FVIII) | When the first 50 PUP have reached at least 50 exposure dates. (Expected to reach between 6 - 18 months) | ||
Primary | Incidence of inhibitory antibodies against coagulation factor VIII (FVIII) | At the end of the trial. End of trial will be up to 4 years after the patient has reached 100 exposure dates. (Expected to reach between 12 - 60 months) | ||
Secondary | Frequency of adverse events including serious adverse events and medical events of special interest | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Incidence of confirmed high titre inhibitors (defined as inhibitor titre above 5 Bethesda Units (BU) | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Number of breakthrough bleeding episodes during prophylaxis with turoctocog alfa pegol (N8-GP) (annualised bleeding rate) | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Haemostatic effect of N8-GP in treatment of bleeding episodes, assessed by a predefined 4-point haemostatic response scale ("excellent", "good", "moderate" and "none") | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Consumption of N8-GP for prophylaxis (number of injections and U/Kg per month and per year) | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Consumption of N8-GP for treatment of bleeding episodes (number of injections and U/Kg required per bleeding episode) | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Total consumption of N8-GP per patient (prevention and treatment of bleeding episodes) per month and annualised value | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days | ||
Secondary | Outcome of immune tolerance induction (ITI), assessed by a predefined 4-point ITI outcome scale ("success", "partial success", "failure", "other") | When the first 50 PUPs have reached at least 50 exposure days, and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00978380 -
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
|
Phase 3 | |
Completed |
NCT02568202 -
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
|
N/A | |
Completed |
NCT01949792 -
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
|
Phase 1 | |
Completed |
NCT01205724 -
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
|
Phase 1 | |
Completed |
NCT01562587 -
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
|
Phase 1 | |
Completed |
NCT00108797 -
Trial of NovoSeven® in Haemophilia - Joint Bleeds
|
Phase 4 | |
Completed |
NCT01493778 -
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
|
Phase 3 | |
Completed |
NCT02490787 -
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
|
Phase 1 | |
Completed |
NCT00951405 -
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
|
Phase 2 | |
Completed |
NCT01876745 -
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
|
N/A | |
Completed |
NCT02920398 -
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
|
Phase 1 | |
Completed |
NCT00984126 -
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
|
Phase 3 | |
Completed |
NCT01228669 -
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
|
Phase 1 | |
Completed |
NCT01988532 -
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
|
N/A | |
Completed |
NCT01234545 -
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
|
N/A | |
Completed |
NCT01779921 -
Treatment of Congenital Factor VII Deficiency
|
N/A | |
Completed |
NCT01563471 -
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02941354 -
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
|
Phase 1 | |
Completed |
NCT02241694 -
To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives
|
N/A | |
Completed |
NCT01238367 -
A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
|
Phase 1 |